209 related articles for article (PubMed ID: 36470543)
21. [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
Wang Q; Peng W; Jiang M; Wu L
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):182-188. PubMed ID: 32102135
[TBL] [Abstract][Full Text] [Related]
22. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
23. Advances in antibody therapeutics targeting small-cell lung cancer.
Lu H; Jiang Z
Adv Clin Exp Med; 2018 Sep; 27(9):1317-1323. PubMed ID: 29790694
[TBL] [Abstract][Full Text] [Related]
24. Abscopal effect of radiation therapy and nivolumab in a patient with combined small-cell lung cancer: a case report.
Wang W; Li L; Wu S; Shen J; Huang C; Chen Y; Li S
Immunotherapy; 2022 Aug; 14(12):909-914. PubMed ID: 35787148
[TBL] [Abstract][Full Text] [Related]
25. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
26. Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance.
Jin Y; Chen Y; Qin Z; Hu L; Guo C; Ji H
Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(6):948-955. PubMed ID: 37249335
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
28. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.
Quintanal-Villalonga A; Taniguchi H; Hao Y; Chow A; Zhan YA; Chavan SS; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Offin M; Ciampricotti M; Ray-Kirton J; Egger J; Bhanot U; Linkov I; Asher M; Roehrl MH; Qiu J; de Stanchina E; Hollmann TJ; Koche RP; Sen T; Poirier JT; Rudin CM
Cancer Res; 2022 Feb; 82(3):472-483. PubMed ID: 34815254
[TBL] [Abstract][Full Text] [Related]
30. Small cell lung cancer; recent advances of its biology and therapeutic perspective.
Hayashi R; Inomata M
Respir Investig; 2022 Mar; 60(2):197-204. PubMed ID: 34896039
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Pavan A; Attili I; Pasello G; Guarneri V; Conte PF; Bonanno L
J Immunother Cancer; 2019 Aug; 7(1):205. PubMed ID: 31383005
[TBL] [Abstract][Full Text] [Related]
32. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
33. Signal pathways and precision therapy of small-cell lung cancer.
Yuan M; Zhao Y; Arkenau HT; Lao T; Chu L; Xu Q
Signal Transduct Target Ther; 2022 Jun; 7(1):187. PubMed ID: 35705538
[TBL] [Abstract][Full Text] [Related]
34. Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment.
Zhu Y; Cui Y; Zheng X; Zhao Y; Sun G
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166557. PubMed ID: 36162624
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
36. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
37. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
38. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
39. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
40. Ganitumab for the treatment of small-cell lung cancer.
Martínez P; Sales Fidalgo PA; Felip E
Expert Opin Investig Drugs; 2014 Oct; 23(10):1423-32. PubMed ID: 25189625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
